|
JP2020054398A
|
|
Anti-cd38 antibodies and fusions with attenuated interferon alpha-2b
|
|
US2018305460A1
|
|
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
JP2018087218A
|
|
Anti-cd38 antibodies and fusions with attenuated interferon alpha-2b
|
|
WO2018014068A1
|
|
Attenuated type i ifn cd47 combination therapy
|
|
CA3030926A1
|
|
Anti-cd47 combination therapy
|
|
MX2019014848A
|
|
Anti-cd38 antibodies and fusions with attenuated alpha-2b interferon.
|
|
CA2965414A1
|
|
Interferon .alpha.2.beta. variants
|
|
EP3137505A2
|
|
Combination of lenalidomide and polypeptide construct, and uses thereof
|
|
EA033115B1
|
|
Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b
|
|
NZ742073A
|
|
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
KR20190123353A
|
|
Polypeptide constructs and uses thereof
|
|
AU2012323781A1
|
|
Antibodies to CD1d
|
|
AU2012315474A1
|
|
Antibodies against TL1a and uses thereof
|
